Jasmeen Uppal
Rheumatology · Saint Paul, MNNPI 1811549314
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Amgen at 30.7% of the total. Reporting peaked in 2024 at $477 and has fallen 96.2% since, to $18 in 2025.
Across 47 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$339
- Aurinia Pharma U.S., Inc.$203
- Boehringer Ingelheim$197
- Genentech USA, Inc.$80
- AbbVie$74
- Sobi, Inc$46
- plus $167 from 7 others
What the payments were for
- Food & beverage$1,08698%
- Education$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 13 | $339 |
| Aurinia Pharma U.S., Inc. | 10 | $203 |
| Boehringer Ingelheim | 7 | $197 |
| Genentech USA, Inc. | 4 | $80 |
| AbbVie | 3 | $74 |
| Sobi, Inc | 2 | $46 |
| Johnson & Johnson | 1 | $42 |
| AstraZeneca | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Octapharma USA, Inc. | 1 | $21 |
| Novartis | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavneos$125
How this compares
$1,106 in reported general payments places this provider in the 75th percentile of 121 rheumatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 72 | $623,677 |
| Enbrel SureclickEtanercept | 29 | $210,490 |
| Humira PenAdalimumab | 19 | $187,143 |
| Actemra ActpenTocilizumab | 24 | $106,229 |
| Mycophenolate Mofetil | 51 | $9,326 |
| MethotrexateMethotrexate Sodium | 166 | $2,700 |
| Hydroxychloroquine Sulfate | 81 | $2,650 |
| Colchicine | 30 | $2,042 |
| Leflunomide | 27 | $843 |
| Sulfasalazine | 18 | $660 |
| Celecoxib | 12 | $443 |
| Gabapentin | 46 | $361 |
| Prednisone | 65 | $330 |
| Nifedipine ErNifedipine | 11 | $201 |
| Duloxetine Hcl | 19 | $91 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Saint Paul
- Thomas IrvinSaint Paul$359
- Michele ObertSaint Paul$315
- David EwartSaint Paul$250
- Matthew McElweeSaint Paul$142
- Martha GranditsSaint Paul$119
- Prasanthi MeagherSaint Paul$100
- Rayhaan AkramSaint Paul$100
- Asim KhanMaple Grove$1.2M
- Parastoo FazeliMinneapolis$149K
- Robert TierneySt Louis Park$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.